

Sul
E3
~~46. A method for treating damaged locus ceruleus neurons or axons in a mammal~~
comprising nonintracranial administration of an IGF in an amount effective to treat the locus
~~ceruleus neurons or axons~~

47. The method of claim 46, wherein the IGF is IGF-I.

48. The method of claim 47, wherein IGF-I is administered in an amount from about
0.1 µg/kg body weight/day up to about 4 mg/kg body weight/day.

49. The method of claim 47, wherein the mammal is a human.

D
50. The method of claim 47, wherein the locus cereleus is damaged due to traumatic
injury.

51. The method of claim 47, wherein the locus cereleus is damaged due to stroke.

52. The method of claim 46, wherein the IGF is IGF-II.

53. The method of claim 52, wherein IGF-II is administered in an amount from about
0.1 µg/kg body weight/day up to about 4 mg/kg body weight/day.

54. The method of claim 52, wherein the mammal is a human.

55. The method of claim 52, wherein the locus cereleus is damaged due to traumatic
injury.

56. The method of claim 52, wherein the locus cereleus is damaged due to stroke.

Sul
E4
57. A method for treating injury to the ~~central nervous system comprising~~
~~nonintracranial administration of an IGF in an amount effective to treat the injury.~~

58. The method of claim 57, wherein the IGF is IGF-I.

59. The method of claim 58, wherein IGF-I is administered in an amount from about
0.1 µg/kg body weight/day up to about 4 mg/kg body weight/day.

60. The method of claim 58, wherein the mammal is a human.
61. The method of claim 58, wherein the central nervous system is damaged due to traumatic injury.
62. The method of claim 58, wherein the central nervous system is damaged due to stroke.
63. The method of claim 57, wherein the IGF is IGF-II.
64. The method of claim 63, wherein IGF-II is administered in an amount from about 0.1 µg/kg body weight/day up to about 4 mg/kg body weight/day.
65. The method of claim 63, wherein the mammal is a human.
66. The method of claim 63, wherein the central nervous system is damaged due to traumatic injury.
67. The method of claim 63, wherein the central nervous system is damaged due to stroke.--

REMARKS

Applicant appreciates the opportunity to participate in the Examiner interview on August 3, 1998. The following remarks incorporate the statements and suggestions discussed at the interview.

I. Request to Withdraw Final Status of Office Action

Applicant requests withdrawal of the finality of the Office Action mailed May 1, 1998. The May 1, 1998 Office Action was the first action in this continued prosecution application (CPA). This CPA was filed February 17, 1998 and a Preliminary Amendment was filed April 13, 1998 adding new claims 24-45. In making the first Office action final, the Examiner stated